So, that was just serendipitous that it got figured out with type 2 diabetes first
GLP-1 weight loss skin tightening is one of the most searched topics among patients on these medications, and for good reason
The study's primary objectives were three key secondary endpoints, controlled for type I error: the percent change in body weight from baseline to week 176 and the onset of type 2 diabetes during the 176-week and 193-week periods
SURMOUNT-1 data show meaningful weight loss at all three maintenance dose tiers: approximately 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg
Since muscles have a very good blood supply, the medication is absorbed quickly
In February 2024, we announced that the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo